eXmoor to showcase rapid growth of cell and gene therapy at Institute of Chemical Engineers’ webinar

Manufacturing consultancy eXmoor pharma is to present on the role of Process Engineering in Cell and Gene Therapy (CGT) Manufacturing to an audience from the Institute of Chemical Engineers (IChemE) at a webinar event on 4^th February.

Chief executive officer Angela Osborne will host IChemE’s latest free-to-attend webinar following her award of the prestigious industry accolade the Donald Medal last year.

Angela will explore the rapid growth of CGT and how it is now at a global scale, attracting significant VC and PE interest. The session will include examples in both process and facility development where process engineering principles can and have been applied to accelerate the route to market.

IChemE is the leading global professional qualifying body for chemical, biochemical and process engineers which exists to advance the worldwide contribution of chemical engineering for the benefit of society.

Angela, originally a biochemical engineer from UCL (BSc and PhD), is the founder and CEO of eXmoor pharma, a Bristol-based process development and manufacturing partner working globally in cell and gene therapies and biopharmaceuticals, which was founded in 2004.

Last year, Angela was awarded IChemE’s Donald Medal. Named after a long-serving honorary secretary of IChemE and former Ramsay Professor at University College London, Maxwell Bruce Donald. The accolade is  awarded annually by the Biochemical Engineering Special Interest Group (BESIG).

Angela received the award in recognition of her pioneering work in the field of cell and gene therapy manufacturing. She is the first female recipient of the award since its fruition in 1989.

Commenting, Angela said: “I felt very honoured to receive the medal last year and it is humbling tobe in the company of previous winners such as Peter Dunnill and Malcolm Lilly, who pioneered biochemical engineering. I am delighted to be presenting the latest innovations and work from the cell and gene therapy manufacturing sector. I hope that attendees will gain an understanding of the importance of process engineering principles in process and facility development within this area of manufacturing.”

The webinar on 4^th February is aimed at biochemical engineers with an interest in cell and gene therapy.

To register for the webinar please visit: https://www.icheme.org/membership/communities/special-interest-groups/biochemical-engineering/events/04-02-21-process-engineering-in-cell-and-gene-therapy-manufacturing/